CCCC Accounts Payable vs Net Tangible Assets Analysis

CCCC Stock

USD 5.00 0.02 0.40%

C4 TherapeuticsInc financial indicator trend analysis is way more than just evaluating C4 TherapeuticsInc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether C4 TherapeuticsInc is a good investment. Please check the relationship between C4 TherapeuticsInc Accounts Payable and its Net Tangible Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.

Accounts Payable vs Net Tangible Assets

Accounts Payable vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of C4 TherapeuticsInc Accounts Payable account and Net Tangible Assets. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between C4 TherapeuticsInc's Accounts Payable and Net Tangible Assets is 0.42. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of C4 TherapeuticsInc, assuming nothing else is changed. The correlation between historical values of C4 TherapeuticsInc's Accounts Payable and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of C4 TherapeuticsInc are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Accounts Payable i.e., C4 TherapeuticsInc's Accounts Payable and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

0.42

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents C4 TherapeuticsInc obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of C4 TherapeuticsInc are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most indicators from C4 TherapeuticsInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into C4 TherapeuticsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.At present, C4 TherapeuticsInc's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 2.13, whereas Selling General Administrative is forecasted to decline to about 27.4 M.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.9M	3.6M	7.7M	8.1M
Interest Income	387K	3.6M	8.6M	9.0M

Depreciation And Amortization Interest Income

C4 TherapeuticsInc fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.79	0.67	0.95	1.0	-0.91	0.99	0.67	0.78	-0.16	-0.78	0.44	0.57	0.86	0.73	0.74	0.96	-0.81	0.84	-0.98	0.7	0.96	0.87	-0.98	1.0	0.7
Short Long Term Debt Total	0.79		0.54	0.76	0.79	-0.91	0.81	0.98	0.55	0.26	-0.89	0.02	0.26	0.83	0.81	0.96	0.76	-0.7	0.77	-0.77	0.99	0.84	0.9	-0.76	0.79	0.99
Other Current Liab	0.67	0.54		0.75	0.67	-0.8	0.7	0.51	0.25	-0.43	-0.85	0.39	0.7	0.56	0.26	0.64	0.64	-0.68	0.74	-0.75	0.53	0.59	0.81	-0.77	0.66	0.53
Total Current Liabilities	0.95	0.76	0.75		0.95	-0.91	0.94	0.64	0.76	-0.28	-0.8	0.62	0.67	0.82	0.69	0.71	0.96	-0.94	0.95	-0.97	0.67	0.94	0.87	-0.95	0.95	0.67
Total Stockholder Equity	1.0	0.79	0.67	0.95		-0.9	0.99	0.67	0.76	-0.19	-0.78	0.46	0.6	0.84	0.7	0.74	0.96	-0.82	0.85	-0.99	0.69	0.95	0.86	-0.98	1.0	0.7
Other Liab	-0.91	-0.91	-0.8	-0.91	-0.9		-0.91	-0.85	-0.64	0.02	0.96	-0.27	-0.48	-0.88	-0.76	-0.89	-0.87	0.82	-0.88	0.91	-0.87	-0.91	-0.99	0.92	-0.9	-0.87
Net Tangible Assets	0.99	0.81	0.7	0.94	0.99	-0.91		0.71	0.68	-0.2	-0.8	0.42	0.62	0.84	0.66	0.79	0.95	-0.82	0.85	-0.98	0.73	0.93	0.87	-0.97	0.99	0.73
Property Plant And Equipment Net	0.67	0.98	0.51	0.64	0.67	-0.85	0.71		0.4	0.35	-0.87	-0.12	0.17	0.77	0.74	0.97	0.63	-0.6	0.69	-0.65	1.0	0.74	0.86	-0.65	0.66	1.0
Current Deferred Revenue	0.78	0.55	0.25	0.76	0.76	-0.64	0.68	0.4		0.03	-0.44	0.48	0.25	0.7	0.85	0.35	0.78	-0.68	0.64	-0.72	0.41	0.84	0.59	-0.7	0.77	0.43
Net Debt	-0.16	0.26	-0.43	-0.28	-0.19	0.02	-0.2	0.35	0.03		0.04	-0.74	-0.86	0.26	0.44	0.2	-0.31	0.35	-0.29	0.3	0.31	0.04	0.06	0.31	-0.19	0.33
Retained Earnings	-0.78	-0.89	-0.85	-0.8	-0.78	0.96	-0.8	-0.87	-0.44	0.04		-0.15	-0.49	-0.74	-0.62	-0.9	-0.76	0.75	-0.83	0.82	-0.88	-0.77	-0.96	0.83	-0.77	-0.88
Accounts Payable	0.44	0.02	0.39	0.62	0.46	-0.27	0.42	-0.12	0.48	-0.74	-0.15		0.75	0.19	0.09	-0.02	0.57	-0.72	0.63	-0.51	-0.09	0.4	0.19	-0.48	0.46	-0.09
Cash	0.57	0.26	0.7	0.67	0.6	-0.48	0.62	0.17	0.25	-0.86	-0.49	0.75		0.17	-0.03	0.29	0.7	-0.71	0.7	-0.7	0.2	0.39	0.4	-0.7	0.6	0.18
Non Current Assets Total	0.86	0.83	0.56	0.82	0.84	-0.88	0.84	0.77	0.7	0.26	-0.74	0.19	0.17		0.85	0.81	0.73	-0.68	0.73	-0.79	0.78	0.94	0.89	-0.77	0.84	0.8
Non Currrent Assets Other	0.73	0.81	0.26	0.69	0.7	-0.76	0.66	0.74	0.85	0.44	-0.62	0.09	-0.03	0.85		0.65	0.68	-0.6	0.63	-0.64	0.73	0.87	0.75	-0.63	0.71	0.76
Other Assets	0.74	0.96	0.64	0.71	0.74	-0.89	0.79	0.97	0.35	0.2	-0.9	-0.02	0.29	0.81	0.65		0.67	-0.65	0.74	-0.73	0.97	0.76	0.89	-0.72	0.73	0.97
Cash And Short Term Investments	0.96	0.76	0.64	0.96	0.96	-0.87	0.95	0.63	0.78	-0.31	-0.76	0.57	0.7	0.73	0.68	0.67		-0.9	0.9	-0.98	0.66	0.91	0.81	-0.97	0.97	0.66
Net Receivables	-0.81	-0.7	-0.68	-0.94	-0.82	0.82	-0.82	-0.6	-0.68	0.35	0.75	-0.72	-0.71	-0.68	-0.6	-0.65	-0.9		-0.99	0.86	-0.63	-0.83	-0.76	0.84	-0.82	-0.62
Common Stock Shares Outstanding	0.84	0.77	0.74	0.95	0.85	-0.88	0.85	0.69	0.64	-0.29	-0.83	0.63	0.7	0.73	0.63	0.74	0.9	-0.99		-0.89	0.71	0.85	0.83	-0.87	0.84	0.71
Non Current Liabilities Total	-0.98	-0.77	-0.75	-0.97	-0.99	0.91	-0.98	-0.65	-0.72	0.3	0.82	-0.51	-0.7	-0.79	-0.64	-0.73	-0.98	0.86	-0.89		-0.68	-0.92	-0.87	1.0	-0.99	-0.68
Capital Lease Obligations	0.7	0.99	0.53	0.67	0.69	-0.87	0.73	1.0	0.41	0.31	-0.88	-0.09	0.2	0.78	0.73	0.97	0.66	-0.63	0.71	-0.68		0.75	0.87	-0.67	0.69	1.0
Other Current Assets	0.96	0.84	0.59	0.94	0.95	-0.91	0.93	0.74	0.84	0.04	-0.77	0.4	0.39	0.94	0.87	0.76	0.91	-0.83	0.85	-0.92	0.75		0.89	-0.9	0.95	0.77
Other Stockholder Equity	0.87	0.9	0.81	0.87	0.86	-0.99	0.87	0.86	0.59	0.06	-0.96	0.19	0.4	0.89	0.75	0.89	0.81	-0.76	0.83	-0.87	0.87	0.89		-0.88	0.86	0.88
Total Liab	-0.98	-0.76	-0.77	-0.95	-0.98	0.92	-0.97	-0.65	-0.7	0.31	0.83	-0.48	-0.7	-0.77	-0.63	-0.72	-0.97	0.84	-0.87	1.0	-0.67	-0.9	-0.88		-0.98	-0.67
Net Invested Capital	1.0	0.79	0.66	0.95	1.0	-0.9	0.99	0.66	0.77	-0.19	-0.77	0.46	0.6	0.84	0.71	0.73	0.97	-0.82	0.84	-0.99	0.69	0.95	0.86	-0.98		0.69
Property Plant And Equipment Gross	0.7	0.99	0.53	0.67	0.7	-0.87	0.73	1.0	0.43	0.33	-0.88	-0.09	0.18	0.8	0.76	0.97	0.66	-0.62	0.71	-0.68	1.0	0.77	0.88	-0.67	0.69

Click cells to compare fundamentals

C4 TherapeuticsInc Account Relationship Matchups

C4 TherapeuticsInc fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	118.3M	400.1M	506.8M	430.8M	376.5M	362.8M
Short Long Term Debt Total	13.7M	22.9M	42.9M	87.2M	71.0M	46.2M
Other Current Liab	6.7M	9.5M	13.6M	2.9M	20.6M	21.7M
Total Current Liabilities	33.6M	43.9M	51.2M	44.5M	42.8M	44M
Total Stockholder Equity	(112.0M)	280.8M	389.6M	289.2M	246.1M	185.9M
Other Liab	72.7M	53.6M	24.4M	16.9M	15.2M	14.4M
Net Tangible Assets	(112.0M)	280.8M	389.6M	289.2M	332.6M	168.9M
Property Plant And Equipment Net	18.9M	16.6M	35.1M	77.5M	71.1M	43.9M
Current Deferred Revenue	20.7M	27.6M	31.8M	33.5M	15.5M	27.2M
Net Debt	(76.8M)	(158.8M)	(33.2M)	57.4M	(55.6M)	(58.4M)
Retained Earnings	(117.5M)	(183.8M)	(267.7M)	(395.9M)	(528.4M)	(502.0M)
Accounts Payable	5.4M	5.7M	4.5M	1.2M	1.4M	2.6M
Cash	90.5M	181.7M	76.1M	29.8M	126.6M	99.2M
Non Current Assets Total	21.5M	19.1M	181.1M	143.3M	105.3M	90.4M
Cash And Short Term Investments	90.5M	371.7M	309.3M	337.1M	253.7M	256.4M
Net Receivables	4.6M	4.5M	5.7M	1.5M	11.8M	15.3M
Common Stock Shares Outstanding	43.0M	43.1M	46.0M	48.9M	49.6M	45.0M
Liabilities And Stockholders Equity	118.3M	400.1M	506.8M	430.8M	376.5M	362.8M
Non Current Liabilities Total	196.6M	75.5M	65.9M	97.1M	87.6M	96.7M
Capital Lease Obligations	13.7M	12.9M	32.1M	75.7M	71.0M	40.3M
Other Current Assets	1.6M	4.8M	10.7M	9.9M	5.7M	6.2M
Other Stockholder Equity	(105.5M)	64.5M	658.1M	689.3M	774.6M	813.3M
Total Liab	230.2M	119.3M	117.2M	141.6M	130.3M	128.7M
Net Invested Capital	(112.0M)	290.8M	400.4M	300.7M	246.1M	191.8M
Property Plant And Equipment Gross	18.9M	16.6M	42.0M	85.6M	78.9M	48.1M
Total Current Assets	96.8M	381.0M	325.7M	287.6M	271.2M	272.4M
Accumulated Other Comprehensive Income	(1K)	13K	(775K)	(4.1M)	(127K)	(133.4K)
Net Working Capital	63.1M	337.2M	274.4M	243.0M	228.4M	228.4M
Short Term Debt	880K	1.0M	1.3M	7.0M	5.2M	3.0M
Property Plant Equipment	18.9M	16.6M	3.1M	7.4M	6.7M	10.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether C4 TherapeuticsInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 TherapeuticsInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeuticsinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeuticsinc Stock:

How To Invest In CCCC

Details

Is CCCC Stock a good investment?

Details

What is C4 TherapeuticsInc's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.

Note that the C4 TherapeuticsInc information on this page should be used as a complementary analysis to other C4 TherapeuticsInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for CCCC Stock analysis

When running C4 TherapeuticsInc's price analysis, check to measure C4 TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 TherapeuticsInc is operating at the current time. Most of C4 TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of C4 TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 TherapeuticsInc's price. Additionally, you may evaluate how the addition of C4 TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.

	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital

Is C4 TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 TherapeuticsInc. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.37)

Revenue Per Share

0.368

Quarterly Revenue Growth

(0.19)

Return On Assets

(0.21)

Return On Equity

(0.48)

The market value of C4 TherapeuticsInc is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is C4 TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 TherapeuticsInc's market value can be influenced by many factors that don't directly affect C4 TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between C4 TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CCCC Accounts Payable vs Net Tangible Assets Analysis

Accounts Payable vs Net Tangible Assets

Accounts Payable vs Net Tangible Assets Correlation Analysis

Correlation Coefficient

Accounts Payable

Net Tangible Assets

C4 TherapeuticsInc fundamental ratios Correlations

C4 TherapeuticsInc Account Relationship Matchups

High Positive Relationship

High Negative Relationship

C4 TherapeuticsInc fundamental ratios Accounts

Also Currently Popular

Complementary Tools for CCCC Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Capital Lease Obligations	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Liab	+ 1.0	Non Current Liabilities Total

Net Invested Capital	- 0.99	Non Current Liabilities Total
Common Stock Shares Outstanding	- 0.99	Net Receivables
Other Stockholder Equity	- 0.99	Other Liab
Non Current Liabilities Total	- 0.99	Total Stockholder Equity
Net Invested Capital	- 0.98	Total Liab
Non Current Liabilities Total	- 0.98	Cash And Short Term Investments